Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - tériflunomide - la sclérose en plaques, sep récurrente-rémittente - les immunosuppresseurs sélectifs de la - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - fumarate de diméthyle - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppresseurs - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - néoplasmes prostatiques - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Union européenne - français - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - asthme - les médicaments pour les maladies respiratoires obstructives, - budesonide / formotérol teva pharma b. est indiqué chez les adultes de 18 ans et plus seulement. asthmabudesonide/formotérol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Union européenne - français - EMA (European Medicines Agency)

taw pharma (ireland) limited - chlorhydrate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agents antithrombotiques - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - chlorhydrate de nébivolol 5,45 mg - eq. nébivolol 5 mg; hydrochlorothiazide 12,5 mg - comprimé pelliculé - 5 mg - 12,5 mg - chlorhydrate de nébivolol 5.45 mg; hydrochlorothiazide 12.5 mg - nebivolol and thiazides

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - chlorhydrate de nébivolol 5,45 mg - eq. nébivolol 5 mg; hydrochlorothiazide 25 mg - comprimé pelliculé - 5 mg - 25 mg - chlorhydrate de nébivolol 5.45 mg; hydrochlorothiazide 25 mg - nebivolol and thiazides

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - chlorhydrate de nébivolol 5,45 mg - eq. nébivolol 5 mg; hydrochlorothiazide 12,5 mg - comprimé pelliculé - nebivolol and thiazides

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - chlorhydrate de nébivolol 5,45 mg - eq. nébivolol 5 mg; hydrochlorothiazide 25 mg - comprimé pelliculé - nebivolol and thiazides

Union européenne - français - EMA (European Medicines Agency)

pari pharma gmbh - la tobramycine - cystic fibrosis; respiratory tract infections - les antibactériens à usage systémique, , antibactériens aminosides - vantobra est indiqué pour le traitement de l'infection pulmonaire chronique due à pseudomonas aeruginosa chez les patients âgés de 6 ans et plus atteints de fibrose kystique (fk). la considération devrait être donnée à des recommandations officielles concernant l'utilisation appropriée des antibactériens.